MiR-194-5p might be a Potential Biomarker for Type 2 Diabetes Mellitus

Dadbinpour, Ali; Dehghanian, Mehran; Vahidi Mehrjardi, Mohammad Yahya

Volume 16, Issue 3 (8-2024) IJDO 2024, 16(3): 167-173 | Back to browse issues page

Mendeley

Zotero

RefWorks

Dadbinpour A, Dehghanian M, Vahidi Mehrjardi M Y. MiR-194-5p might be a Potential Biomarker for Type 2 Diabetes Mellitus. IJDO 2024; 16 (3) :167-173
URL: http://ijdo.ssu.ac.ir/article-1-886-en.html

MiR-194-5p might be a Potential Biomarker for Type 2 Diabetes Mellitus

Ali Dadbinpour

, Mehran Dehghanian

, Mohammad Yahya Vahidi Mehrjardi ^*

Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Abstract: (241 Views)

Objective: Type 2 diabetes mellitus (T2DM) incidence is increasing around the world as a progressive metabolic condition. The miRNA expression profile changes in the early stages of diabetes in body fluids. It can help in early diagnosis of diabetes, which reduces diabetes-related mortality. In this study, miR-194-5p gene expression levels in diabetic and pre-diabetic patients will be examined and compared to the healthy controls.
Materials and Methods: The expression levels of miR-194-5p were evaluated in 90 participants, referred to Yazd diabetes centers (Iran) in 2022, including 30 T2DM, 30 prediabetics, and 30 healthy subjects by real-time PCR. The potential pathways affected by microRNA were fitted to the Enrichr web server by applying target genes predicted to miR-194-5p in the Target Scan Human 7.2 database.
Results: The results of these studies indicate a gradual decrease in miR-194-5p expression levels in prediabetic and T2DM patients compared to healthy controls (P< 0.001). The role of the miR-194-5p target genes in T2DM-related signaling pathways such as the Wnt and TGF-beta pathways was also determined.
Conclusion: The results indicate that miR-194-5p is a potential biomarker for the early diagnosis of T2DM due to its down-regulation in the serum of prediabetics and diabetics compared to healthy subjects.

Keywords: T2DM, miR-194-5p, Gene expression, Biomarker

Full-Text [PDF 467 kb] (108 Downloads)

Type of Study: Research | Subject: Special
Received: 2024/03/4 | Accepted: 2024/07/5 | Published: 2024/08/20

References

1. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Frontiers in endocrinology. 2017;8:6. [DOI:10.3389/fendo.2017.00006]

2. Abusalah MA, Albaker W, Al-Bsheish M, Alsyouf A, Al-Mugheed K, Issa MR, et al. Prevalence of type 2 diabetes mellitus in the general population of Saudi Arabia, 2000-2020: A systematic review and meta-analysis of observational studies. Saudi Journal of Medicine & Medical Sciences. 2023;11(1):1-0. [DOI:10.4103/sjmms.sjmms_394_22]

3. Papademetriou V, Lovato L, Tsioufis C, Cushman W, Applegate WB, Mottle A, et al. Effects of high density lipoprotein raising therapies on cardiovascular outcomes in patients with type 2 diabetes mellitus, with or without renal impairment: The action to control cardiovascular risk in diabetes study. American journal of nephrology. 2017;45(2):136-45. [DOI:10.1159/000453626]

4. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology. 2016;101(1):157-66. [DOI:10.1210/jc.2015-3167]

5. Rahman F, McEvoy JW, Ohkuma T, Marre M, Hamet P, Harrap S, et al. Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial. Hypertension. 2019;73(6):1291-9. [DOI:10.1161/HYPERTENSIONAHA.118.12414]

6. Dehghan Tezerjani M, Vahidi Mehrjardi MY, Kalantar SM, Dehghani M. Genetic susceptibility to transient and permanent neonatal diabetes mellitus. International Journal of Pediatrics. 2015;3(6):1073-81.

7. Addissouky T, Ali M, El Sayed IE, Wang Y. Revolutionary innovations in diabetes research: from biomarkers to genomic medicine. Iranian journal of diabetes and obesity. 2023;15(4):228-42. [DOI:10.18502/ijdo.v15i4.14556]

8. Razavi Z, Sadri H. Environmental Factors before the Onset of Type 1 Diabetes Mellitus: A Case-Control Study.Iranian Journal of Diabetes and Obesity. 2022;14(3):152-8. [DOI:10.18502/ijdo.v14i3.10741]

9. Rahvarzadeh Z, Dehghanian M, Mehrjardi MY, Ashkezari MD. Investigating the Relation between LCK Gene Expression with Type 2 Diabetes Patients in Yazd Diabetes Research Center. Iranian journal of diabetes and obesity.2022;14(1):14-9. [DOI:10.18502/ijdo.v14i1.8736]

10. Deng X, Liu Y, Luo M, Wu J, Ma R, Wan Q, et al. Circulating miRNA-24 and its target YKL-40 as potential biomarkers in patients with coronary heart disease and type 2 diabetes mellitus. Oncotarget. 2017;8(38):63038. [DOI:10.18632/oncotarget.18593]

11. Fabbri M, Croce CM, Calin GA. MicroRNAs. The Cancer Journal. 2008;14(1):1-6. [DOI:10.1097/PPO.0b013e318164145e]

12. Ma J, Wang J, Liu Y, Wang C, Duan D, Lu N, et al. Comparisons of serum miRNA expression profiles in patients with diabetic retinopathy and type 2 diabetes mellitus. Clinics. 2017;72(2):111-5. [DOI:10.6061/clinics/2017(02)08]

13. Zarch SM, Tezerjani MD, Talebi M, Mehrjardi MY. Molecular biomarkers in diabetes mellitus (DM). Medical journal of the Islamic republic of Iran. 2020;34:28.

14. Sadeghzadeh S, Dehghani Ashkezari M, Seifati SM, Vahidi Mehrjardi MY, Dehghan Tezerjani M, Sadeghzadeh S, et al. Circulating MiR-15a and MiR-222 as potential biomarkers of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity.2020:3461-9. [DOI:10.2147/DMSO.S263883]

15. Yarahmadi G, Tavakoli Ataabadi S, Dashti Z, Dehghanian M. A review on expression and regulatory mechanisms of miR-337-3p in cancer. Journal of Biomolecular Structure and Dynamics. 2024:1-10. [DOI:10.1080/07391102.2024.2329294]

16. Moradi M, Mozafari F, Hosseini S, Rafiee R, Ghasemi F. A concise review on impacts of microRNAs in biology and medicine of hepatitis C virus. Gene Reports. 2020;20:100761. [DOI:10.1016/j.genrep.2020.100761]

17. Chen R, Lei S, Jiang T, Zeng J, Zhou S, She Y. Roles of lncRNAs and circRNAs in regulating skeletal muscle development. Acta Physiologica. 2020;228(2):e13356. [DOI:10.1111/apha.13356]

18. Shi Y, Mao X, Cai M, Hu S, Lai X, Chen S, et al. miR-194-5p negatively regulates the proliferation and differentiation of rabbit skeletal muscle satellite cells. Molecular and Cellular Biochemistry. 2021;476:425-33. [DOI:10.1007/s11010-020-03918-0]

19. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic acids research. 2016;44(W1):W90-7. [DOI:10.1093/nar/gkw377]

20. Delić D, Eisele C, Schmid R, Baum P, Wiech F, Gerl M, et al. Urinary exosomal miRNA signature in type II diabetic nephropathy patients. PloS one. 2016;11(3):e0150154. [DOI:10.1371/journal.pone.0150154]

21. Heilmeier U, Hackl M, Skalicky S, Weilner S, Schroeder F, Vierlinger K, et al. Serum miRNA signatures are indicative of skeletal fractures in postmenopausal women with and without type 2 diabetes and influence osteogenic and adipogenic differentiation of adipose tissue-derived mesenchymal stem cells in vitro. Journal of Bone and Mineral Research. 2016;31(12):2173-92. [DOI:10.1002/jbmr.2897]

22. Asrih M, Steffens S. Emerging role of epigenetics and miRNA in diabetic cardiomyopathy. Cardiovascular Pathology. 2013;22(2):117-25. [DOI:10.1016/j.carpath.2012.07.004]

23. Jones A, Danielson KM, Benton MC, Ziegler O, Shah R, Stubbs RS, et al. miRNA signatures of insulin resistance in obesity. Obesity. 2017;25(10):1734-44. [DOI:10.1002/oby.21950]

24. Chen J, Ning C, Mu J, Li D, Ma Y, Meng X. Role of Wnt signaling pathways in type 2 diabetes mellitus. Molecular and Cellular Biochemistry. 2021;476:2219-32. [DOI:10.1007/s11010-021-04086-5]

25. Wang HL, Wang L, Zhao CY, Lan HY. Role of TGF-beta signaling in beta cell proliferation and function in diabetes. Biomolecules. 2022;12(3):373. [DOI:10.3390/biom12030373]

26. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clinica chimica acta. 2012;413(15-16):1163-70. [DOI:10.1016/j.cca.2012.03.021]

27. Latouche C, Natoli A, Reddy-Luthmoodoo M, Heywood SE, Armitage JA, Kingwell BA. MicroRNA-194 modulates glucose metabolism and its skeletal muscle expression is reduced in diabetes. PloS one. 2016;11(5):e0155108. [DOI:10.1371/journal.pone.0155108]

28. Jaeger A, Zollinger L, Saely CH, Muendlein A, Evangelakos I, Nasias D, et al. Circulating microRNAs-192 and-194 are associated with the presence and incidence of diabetes mellitus. Scientific reports. 2018;8(1):14274. [DOI:10.1038/s41598-018-32274-9]

29. Demirsoy İH, Ertural DY, Balci Ş, Çınkır Ü, Sezer K, Tamer L, et al. Profiles of circulating miRNAs following metformin treatment in patients with type 2 diabetes. Journal of medical biochemistry. 2018;37(4):499-506. [DOI:10.2478/jomb-2018-0009]